DE-THE-LYCRA-COMPANY
8.10.2021 01:02:08 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, today announced wins related to its ongoing global efforts to protect its intellectual property (IP), including patents and trademarks, from infringement worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211007005014/en/
The LYCRA Company recently initiated several infringement suits related to its dual core and multi-core patents for denim against third parties in China. These third parties were selling fibers and goods The LYCRA Company deemed to infringe on LYCRA® brand patents.
The Chinese National Intellectual Property Administration (CNIPA) has recently issued a formal decision in support of The LYCRA Company patents for two invalidity challenges. Subsequently, the Jiangsu Authority has informed The LYCRA Company that its patent has been upheld in both these cases.
“We are pleased with the outcome of these two cases with our patents being recognized and upheld by the Chinese authorities,” said Bridget Sciamanna, general counsel for The LYCRA Company. “Protecting our patents and trademarks is a key strategic priority for us in safeguarding the value of our global brands.”
Supporting Customers in Patent Infringement Actions
The LYCRA Company is proud to offer its customers and licensees unmatched support in patent challenges related to its products. In two recent cases, two licensees in Europe turned to The LYCRA Company for technical and legal assistance for their own patent litigation defenses related to the company’s dual core patents. This assistance helped bring about wins for the licensees against the challenger. The presiding court ruled the licensees were not infringing on the other company’s patent.
Fighting Trademark Infringement
As part of its ongoing effort to combat misuse and trademark infringement of its brands globally, The LYCRA Company actively searches online marketplaces to find listings for fabrics and garments that attempt to capitalize on its brands’ positive reputations to drive sales, despite its products not being used.
Only fabrics and garments that have been tested and certified by The LYCRA Company to confirm they contain its fibers and meet its brands’ performance standards are eligible to use its trademarks. Over the past 12 months, the company has successfully removed 2,400 website listings and over 800 social media profiles and posts that infringed on its trademarks.
One of the marketplace websites, a major ecommerce platform in China, immediately acted to correct or take down any listings by third party sellers with trademark infringement issues flagged by The LYCRA Company.
“When our brand names are used on inferior products, it not only damages the consumer’s perception of our brands, it can also diminish the value of a customer's investment in our products,” said Julien Born, ceo of The LYCRA Company. “We have significantly invested in innovation, branding, and marketing for decades, so we will always fight to protect and defend our intellectual property to the fullest extent of the law.”
In the past year, The LYCRA Company has been granted 52 patents globally for innovations across a range of technologies, including new polymers, fabric constructions, stretch and performance technologies, as well as processes for apparel and hygiene applications.
To learn more about LYCRA® brand trademarks, click here .
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit thelycracompany.com .
LYCRA® is a trademark of The LYCRA Company
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
Ant International Launches Industry's First Full-Stack AI-Native Solutions for Payment, Account, FX, Treasury and Growth Operations for Global Businesses18.9.2026 08:53:00 CEST | Press release
In its largest-ever product upgrade, the company unveils an industry-first AI-native, end-to-end full financial stack with close to 100 key products across 4 business pillars.Built on newly upgraded Antom 3-in-1 Transformer, our payment foundation model, and FalconTST, our AI FX & liquidity forecast model.Underpinned by an agent-ready, 2-layered trust and security framework, and a governance-by-design approach that keeps us aligned with evolving compliance and regulatory environments.Autopilots for payment, account and treasury management embedded in the end-to-end financial stack to manage the five main workstreams in natural-language interaction.Introduces agent-native solutions including world's first Account for Agent (AFA) for businesses.89.5% of clients of our main merchant payment service already deployed our FinAI solutions in past 12 months. 81.4% of payment tasks were completed with AI help. In an industry first, Ant International launched a full stack of AI-native solutions
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems18.9.2026 07:00:00 CEST | Press release
2026 Awardees are Corus International,Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh)Commitment of USD 22.2 Million Increases Takeda’s Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health sy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom